Moscow: Russian drugmaker Pharmasyntez has asked the Kremlin to allow it to produce a generic version of U.S.
COVID-19 drug remdesivir, used to treat U.S. President Donald Trump, despite lacking a patent to do so, the firm's director said on Monday.Remdesivir is not available in Russia, Pharmasyntez's director Vikram Punia said, but a generic version cannot be produced and distributed without the consent of the patent-holder, U.S.